---
title: A Closer Look at Last Week’s Financing News — and What Comes Next
description: This week, Orchestra BioMed announced that the Company has secured over $111 million in proceeds and committed capital, following the completion of its strategic transactions as well as concurrent public and private equity offerings.
image: https://www.orchestrabiomed.com/hubfs/Corporate%202.png
---

[![Orchestra BioMed Logo](https://www.orchestrabiomed.com/hubfs/logo-light.png) ](https://www.orchestrabiomed.com/)

×

## Who we are

- [Our Approach](https://www.orchestrabiomed.com/our-approach)
- [Our People](https://www.orchestrabiomed.com/our-people)
- [Careers](https://www.orchestrabiomed.com/careers)

## Our Innovations

- [Pipeline](https://www.orchestrabiomed.com/pipeline)
- [Therapeutic Areas](https://www.orchestrabiomed.com/therapeutic-areas)
- [AVIM Therapy](https://www.orchestrabiomed.com/avim-therapy)
- [Virtue® SAB](https://www.orchestrabiomed.com/virtue-sab)

## Content Hub

## Investor Relations

- [Overview](https://investors.orchestrabiomed.com)
- [News & Events](https://investors.orchestrabiomed.com/news-and-events)
- [Stock Quote & Chart](https://investors.orchestrabiomed.com/stock-quote-and-chart)
- [Analyst Coverage](https://investors.orchestrabiomed.com/analyst-coverage)
- [Corporate Governance](https://investors.orchestrabiomed.com/corporate-governance)
- [Financial & Filings](https://investors.orchestrabiomed.com/financials-and-filings)
- [IR Resources](https://investors.orchestrabiomed.com/ir-contact)

[![Orchestra BioMed Logo](https://www.orchestrabiomed.com/hubfs/logo-light.png) ]({type=EXTERNAL,%20content_id=null,%20href=,%20href_with_scheme=})

☰

## OBIO | A Closer Look at Last Week’s Financing News — and What Comes Next

**A closer look at last week’s financing news — and what comes next**

**Fellow Shareholders: **

This week, Orchestra BioMed announced that the Company has secured [over $111 million](https://protect.checkpoint.com/v2/___https:/investors.orchestrabiomed.com/news-releases/news-release-details/orchestra-biomed-secures-over-111-million-proceeds-and-committed___.YzJ1OnBhdWxiYWtlcm5vdGlmaWVkY29tOmM6bzo0MTJkOTY1M2NjMjg1NTJjNGIzZTU4NGMyMWM4NWU3NDo2OmI4YzI6MmMwMDU2MGMwNWU3Mzg3MzAwZWM0YjQwYWZjYTQ5ZmM2MWQzZTA1ZjE3NTliYWExNzM0YzI5Y2RkZDM4OThjNjpwOlQ6Tg) in proceeds and committed capital, following the completion of its strategic transactions as well as concurrent public and private equity offerings.

Because several interlocking financing mechanisms were announced in rapid succession, we will publish a series of concise blog posts during the first half of August 2025 to highlight the most important elements of this activity for shareholders and other stakeholders.

Today’s post will explain how the recent investments and public offering strengthen our cash position while managing share expansion.

 

#### **What the investments and offering deliver**

The financing package announced last week in total will add **over $111 million **in gross proceeds** **to OBIO’s balance sheet when all the various funding streams are complete, and consists of three basic components – including commitments from Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), an established royalty investor, and also from OBIO’s strategic partner Medtronic, Inc., the global market leader in cardiac rhythm management:

- **Public follow-on offering.**  
  • 9,413,367 shares of common stock and pre-funded warrants to purchase up to an aggregate of 5,136,363 shares of common stock raised gross proceeds of approximately **$40 million** at $2.75 per share.
- **Ligand commitment.**  
  • Non-dilutive **$35 million** commitment for a tiered royalty interest in Orchestra’s future royalty revenues from AVIM Therapy and Virtue SAB as well as a **$5 million** investment in a private placement offering of shares of our common stock at a purchase price of $2.75 per share.
- **Medtronic commitment.**  
  • Non-dilutive **$20 million** commitment for secured note that converts to prepaid royalties upon FDA approval of AVIM therapy, plus an **$11.2 million** investment in a private placement offering of shares of our common stock at a purchase price of $2.75 per share.

Management estimates that these proceeds, combined with cash that was already on the balance sheet or expected to be received in future, will extend OBIO’s projected runway **into the third quarter of 2027, **funding completion of enrollment and follow up of primary endpoints data for the **BACKBEAT global pivotal **study and substantial enrollment of the **Virtue SAB** U.S. coronary pivotal trial. Approximately half of the new capital arrives through royalty or revenue-linked instruments that provide cash without creating/adding dilutive common equity on day one.

Shareholders should note that Ligand is a biopharmaceutical company enabling scientific advancement through supporting clinical development of high-value medicines. The basis for their investment in OBIO was extensive due diligence, backed by decades of institutional knowledge of the healthcare innovation sector. It is meaningful that they made a long-term commitment to OBIO in the form of a capital partnership, the upside of which derives only from the future commercial success of our lead innovation programs.

Also important: industry-leader Medtronic’s ongoing, and now increased, investment in OBIO reflects its commitment to our collaboration and the clinical and commercial potential of AVIM therapy.

Overall, we believe our strategic capital transactions with Medtronic and Ligand along with sophisticated healthcare investors participation in our public offering shows confidence in the transformative potential our technology and partnership-enabled business model. Management believes the completion of the company’s first underwritten public offering also broadened our institutional shareholder base and enhanced liquidity for all shareholders.

Subsequent Form 4 and Schedule 13 filings will confirm that insiders, including Chief Executive Officer **David Hochman**, Perceptive and RTW, also participated in the offering on the same economic terms as external investors, underscoring internal confidence in the Company’s outlook.

 

#### **Liquidity and share expansion, in context**

The follow-on public offering raised the minority portion of the $111 million-plus in proceeds, limiting the amount of new shares OBIO issued in the process of securing significant additional capital resources. The new shares were priced at a modest discount to the market price on the trading day the public offering was announced, in line with what is typical for an offering of this kind, and without any additional dilutive structures such as accompanying common stock warrants which are now frequently issued in similar transaction to provide additional incentives to new investors.  As one of the largest overall financings completed by a company in our range of market capitalization in the healthcare sector, we would highlight several considerations about our completed $111 million financing:

1. **Capital efficiency.** The royalty purchase and revenue-linked note furnish cash without issuing additional common shares at today’s valuation, significantly limiting dilution relative to a pure-equity raise.
2. **High-conviction participation.** Equity purchased and other investment commitments by Ligand and Medtronic along with equity purchased by established healthcare funds signals conviction in the OBIO opportunity.
3. **Multi-year funding clarity.** With the balance sheet now positioned to cover both late-stage clinical programs, Orchestra BioMed can execute on its key clinical milestones (the BACKBEAT study and enrollment for the Virtue SAB trial)without near-term dependence on additional equity-market activity.

Taken together, we believe that the investments and public and private offerings lay the groundwork for additional liquidity in the stock and substantially strengthen our balance sheet.

 

#### **Looking ahead**

Hypertension and atherosclerotic artery disease remain large, global markets with substantial unmet clinical need. Orchestra BioMed’s device-based **AVIM therapy** and **Virtue Sirolimus AngioInfusion Balloon** target high-risk patient populations with these conditions with differentiated mechanisms intended to improve outcomes while fitting seamlessly into existing interventional workflows.

Financial commitments from industry leaders such as **Medtronic** and established biopharma royalty investors like **Ligand** demonstrate strong conviction in the science underlying OBIO’s technologies, as well as in OBIO’s ability to deliver regulatory-submission-ready products for our strategic collaborators to bring to market.

**— Team OBIO**

![BACKBEAT Timeline Update Reinforces Momentum to Pivotal Trial Data Presentation and Regulatory Submissions by Medtronic](https://www.orchestrabiomed.com/hubfs/Regulatory%202.png)

May 2026

##### [BACKBEAT Timeline Update Reinforces Momentum to Pivotal Trial Data Presentation and Regulatory Submissions by Medtronic](https://www.orchestrabiomed.com/hub/backbeat-timeline-update-reinforces-momentum-to-pivotal-trial-data-presentation-and-regulatory-submissions-by-medtronic)

 BACKBEAT Timeline Update Reinforces Momentum to Pivotal Trial Data Presentation and Regulatory Submissions by Medtronic ...

![Strategic Capital Supports Pivotal-Stage Execution](https://www.orchestrabiomed.com/hubfs/Finance%202.png)

May 2026

##### [Strategic Capital Supports Pivotal-Stage Execution](https://www.orchestrabiomed.com/hub/strategic-capital-supports-pivotal-stage-execution)

 Strategic Capital Supports Pivotal-Stage Execution Orchestra BioMed Investor Relations Blog | May 2026 The receipt of $3...

![Strengthening AVIM Therapy’s Regulatory Pathway: A Second FDA Breakthrough Device Designation](https://www.orchestrabiomed.com/hubfs/Regulatory%202.png)

April 2026

##### [Strengthening AVIM Therapy’s Regulatory Pathway: A Second FDA Breakthrough Device Designation](https://www.orchestrabiomed.com/hub/strengthening-avim-therapys-regulatory-pathway-a-second-fda-breakthrough-device-designation)

 Strengthening AVIM Therapy’s Regulatory Pathway: A Second FDA Breakthrough Device Designation Orchestra BioMed Investor ...

![From Blood Pressure Reduction to Cardiac Function: What New AVIM Therapy Data Signal](https://www.orchestrabiomed.com/hubfs/Clinical.png)

April 2026

##### [From Blood Pressure Reduction to Cardiac Function: What New AVIM Therapy Data Signal](https://www.orchestrabiomed.com/hub/from-blood-pressure-reduction-to-cardiac-function-what-new-avim-therapy-data-signal)

 From Blood Pressure Reduction to Cardiac Function: What New AVIM Therapy Data Signal Orchestra BioMed Investor Relations...

![Our Clinical Vision: AVIM Therapy for Hypertensive Heart Disease](https://www.orchestrabiomed.com/hubfs/Clinical%202.png)

March 2026

##### [Our Clinical Vision: AVIM Therapy for Hypertensive Heart Disease](https://www.orchestrabiomed.com/hub/avim-therapy-for-hypertensive-heart-disease)

 Our Clinical Vision: AVIM Therapy for Hypertensive Heart Disease Orchestra BioMed recently announced multiple scientific...

##### Follow us on LinkedIn

[![LinkedIn](https://www.orchestrabiomed.com/hubfs/Assets%202024/skill-icons--linkedin.svg) ](https://www.linkedin.com/company/orchestra-biomed/)

![LinkedIn Post](https://www.orchestrabiomed.com/hubfs/1760457247277.jpg)

 Avi Fischer, M.D., joined forward-thinking leaders exploring the future of treating hypertensive hea...

[Learn more](https://www.linkedin.com/posts/orchestra-biomed_orchestratinginnovation-gamedtechsummit-activity-7383892875350237184-LTyD?utm_source=share&utm_medium=member_desktop&rcm=ACoAACQyoIEBJiu1zf2Qtko6wt17ziSn0Nnd8DA) [![LinkedIn](https://www.orchestrabiomed.com/hubfs/Assets%202024/skill-icons--linkedin.svg) ](https://www.linkedin.com/posts/orchestra-biomed_orchestratinginnovation-gamedtechsummit-activity-7383892875350237184-LTyD?utm_source=share&utm_medium=member_desktop&rcm=ACoAACQyoIEBJiu1zf2Qtko6wt17ziSn0Nnd8DA)

![LinkedIn Post](https://www.orchestrabiomed.com/hubfs/1755711749377.jpg)

 Great ideas need great minds to bring them to life. Our team is dedicated to making a lasting impact...

[Learn more](https://www.linkedin.com/posts/orchestra-biomed_hypertension-orchestratinginnovation-medtechleaders-activity-7369825404204851203-F11N?utm_source=share&utm_medium=member_desktop&rcm=ACoAACQyoIEBJiu1zf2Qtko6wt17ziSn0Nnd8DA) [![LinkedIn](https://www.orchestrabiomed.com/hubfs/Assets%202024/skill-icons--linkedin.svg) ](https://www.linkedin.com/posts/orchestra-biomed_hypertension-orchestratinginnovation-medtechleaders-activity-7369825404204851203-F11N?utm_source=share&utm_medium=member_desktop&rcm=ACoAACQyoIEBJiu1zf2Qtko6wt17ziSn0Nnd8DA)

![LinkedIn Post](https://www.orchestrabiomed.com/hubfs/1758048308117.jpg)

 Where in the world is our CEO? 🌍 David Hochman joined leading voices in hashtag#Cardiology and hash...

[Learn more](https://www.linkedin.com/posts/orchestra-biomed_where-in-the-world-is-our-ceo-activity-7373789069291597826-XREZ?utm_source=share&utm_medium=member_desktop&rcm=ACoAACQyoIEBJiu1zf2Qtko6wt17ziSn0Nnd8DA) [![LinkedIn](https://www.orchestrabiomed.com/hubfs/Assets%202024/skill-icons--linkedin.svg) ](https://www.linkedin.com/posts/orchestra-biomed_where-in-the-world-is-our-ceo-activity-7373789069291597826-XREZ?utm_source=share&utm_medium=member_desktop&rcm=ACoAACQyoIEBJiu1zf2Qtko6wt17ziSn0Nnd8DA)

![LinkedIn Post](https://www.orchestrabiomed.com/hubfs/1753992784636.png)

 Ligand Pharmaceuticals and Medtronic Cardiac and Vascular commit $70 Million in strategic capital to...

[Learn more](https://www.linkedin.com/posts/orchestra-biomed_financing-news-activity-7356780339828051970-t1iK?utm_source=share&utm_medium=member_desktop&rcm=ACoAACQyoIEBJiu1zf2Qtko6wt17ziSn0Nnd8DA) [![LinkedIn](https://www.orchestrabiomed.com/hubfs/Assets%202024/skill-icons--linkedin.svg) ](https://www.linkedin.com/posts/orchestra-biomed_financing-news-activity-7356780339828051970-t1iK?utm_source=share&utm_medium=member_desktop&rcm=ACoAACQyoIEBJiu1zf2Qtko6wt17ziSn0Nnd8DA)

![LinkedIn Post](https://www.orchestrabiomed.com/hubfs/1754658413763.jpg)

 FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT glo...

[Learn more](https://www.linkedin.com/posts/orchestra-biomed_backbeat-global-pivotal-study-protocol-update-activity-7359674332731592704-b_pj?utm_source=share&utm_medium=member_desktop&rcm=ACoAACQyoIEBJiu1zf2Qtko6wt17ziSn0Nnd8DA) [![LinkedIn](https://www.orchestrabiomed.com/hubfs/Assets%202024/skill-icons--linkedin.svg) ](https://www.linkedin.com/posts/orchestra-biomed_backbeat-global-pivotal-study-protocol-update-activity-7359674332731592704-b_pj?utm_source=share&utm_medium=member_desktop&rcm=ACoAACQyoIEBJiu1zf2Qtko6wt17ziSn0Nnd8DA)